Open Orphan #ORPH – Results from the world’s first COVID-19 Characterisation Study February 2, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the results from the world’s first COVID-19 characterisation study, which was a partnership between hVIVO, Imperial College London, the Vaccine Taskforce and Department of Health and Social Care (DHSC), and the Royal Free London NHS Foundation Trust. The results from this landmark study, show that a SARS-CoV-2…

Open Orphan #ORPH – Quotient Limited & hVIVO Partnership to Support Wide-Spread COVID-19 Antibody Testing in the UK May 11, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that Quotient has entered into an exclusive contract with hVIVO to support COVID-19 antibody testing in the UK. The MosaiQ™ by Quotient system and MosaiQ COVID-19 Antibody Microarray will be used by hVIVO to screen…

Open Orphan #ORPH – Quotient Limited & hVIVO Partnership to Support Wide-Spread COVID-19 Antibody Testing in the UK May 11, 2020 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL